



SOLVE
ON.

2024 Incyte Ingenuity Awards in GVHD™ Awarded to Memorial Sloan Kettering Cancer Center and Thomas Jefferson University

Wilmington, Del. – November 1, 2024 – Today, Incyte is proud to announce that Memorial Sloan Kettering Cancer Center (MSK) and Thomas Jefferson University have been selected as the recipients of the 2024 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports two innovative initiatives that address the specific needs of people affected by graft-versus-host disease (GVHD), including patients, care partners and providers.

MSK, in collaboration with MSK’s Bone Marrow Transplant and Rehabilitation division, plans to establish a virtual platform to provide remote physical therapy and rehabilitative care to people with GVHD for its project, *Personalized Virtual GVHD Rehabilitation via a GVHD-Focused Physical Therapy Program*. The platform will utilize audio-visual technology and wearable sensors to deliver customized rehabilitation plans to individuals with GVHD as well as allow physicians to monitor and assess the patients’ physical progress.

Thomas Jefferson University’s project, titled, *The HOPE Program: Holistic and Optimized Patient Empowerment for GVHD*, aims to establish a comprehensive and accessible clinic that provides holistic, patient-centered care to people with chronic GVHD. The clinic will provide acupuncture, meditation, yoga, counseling, music and art therapy, all of which have shown promise in alleviating various symptoms associated with chronic GVHD. The majority of these interventions will be available both in-person and virtually to enhance participation and accommodate people with mobility challenges or those who prefer the comfort of their own homes.

“It’s our pleasure to recognize Memorial Sloan Kettering Cancer Center and Thomas Jefferson University as the recipients of the Incyte Ingenuity Awards in GVHD. These institutions have demonstrated a deep commitment to advancing GVHD research and care, and their innovative projects hold great promise for improving the lives of people impacted by this rare disease,” said Barry Flannelly, Pharm. D., Executive Vice President and General Manager North America, Incyte. “We look forward to seeing the profound impact that these initiatives will have as they address the challenges people living with GVHD face.”

Applications for the 2024 Incyte Ingenuity Awards in GVHD were evaluated by an independent judging panel consisting of five GVHD community experts and advocates, including: Barbara Abernathy, Ph.D., LMHC, President and CEO, Pediatric Oncology Support Team, Inc., Adjunct Faculty, University of Miami Miller School of Medicine and Florida Atlantic University; Alice Houk, Senior Director, Patient and Professional Services, Aplastic Anemia & MDS International Foundation; Pooja Khandelwal, M.D., Member, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical

Center, Associate Professor, UC Department of Pediatrics; Doris Ponce, M.D., Associate Professor of Medicine and GVHD Program Director, Memorial Sloan Kettering Cancer Center; Susan Stewart, Founder and Executive Director, Blood and Marrow Transplant Information Network. To maintain the integrity of the judging process, any judge affiliated with an applying organization was precluded from the review of that organization's application.

To read more about these winning initiatives, and for more information about the Incyte Ingenuity Awards in GVHD, visit <https://www.incyteingenuityawards.com/gvhd/>.

About GVHD

GVHD is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor), where the donated cells initiate an immune response and attack the transplant recipient's organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant¹. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) track and liver.

About Incyte

A global biopharmaceutical company on a mission to *Solve On.*, Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit incyte.com or follow us on social media: [LinkedIn](#), [X](#), [Instagram](#), [Facebook](#), [YouTube](#).

###

Contacts:

Media
Media@incyte.com

Investors
ir@incyte.com

¹Ferrara JL., et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.